<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30649">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707718</url>
  </required_header>
  <id_info>
    <org_study_id>BIPS study</org_study_id>
    <nct_id>NCT02707718</nct_id>
  </id_info>
  <brief_title>Biomarkers for the Early Identification of Sepsis in the Emergency Department</brief_title>
  <acronym>BIPS</acronym>
  <official_title>Early Biomarkers of Sepsis Identification in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bio-Rad Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pitié-Salpêtrière Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocentric prospective study on consecutive patients attending the emergency department and
      suspected to have sepsis. Blood sampling for the measurement of a panel of biomarkers of
      interest in sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of patients admitted to the emergency department (ED) requires investigative
      biological parameters that help clinicians to make the right diagnosis.

      Sepsis concerns patients with infection associated with a systemic inflammatory response.
      While this inflammatory profile is observed in many clinical situations in the ED, the
      challenge is to characterize in these patients suspected of sepsis those who have a real
      infection.

      Currently, no individual biomarker of sepsis is sufficiently discriminant. The objective of
      this study is to measure in patients suspected of sepsis in the emergency department, a
      combination of biomarkers (covering several distinct pathophysiological pathways) that could
      provide high specificity and sensitivity for the diagnostic and prognostic. The originality
      of this study is that compared with patients admitted to intensive care units, patients
      investigated for suspected sepsis in the ED are seen earlier in their medical history and
      usually before any therapeutic intervention (intravenous fluids, antibiotics,
      catecholamines) interfering with several biomarkers of interest.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sepsis diagnosis</measure>
    <time_frame>30-day after inclusion</time_frame>
    <description>Among the patients included in the study with a sepsis suspicion, the primary outcome measure will be a final diagnosis of sepsis adjudicated on the medical file and 30-day follow-up, by an expert panel blind for the biomarkers studied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severe outcome defined by: severe sepsis and/or septic shock and/or ICU admission and/or death in the 30-day follow-up</measure>
    <time_frame>30-day after inclusion</time_frame>
    <description>Among the patients included in the study with a sepsis suspicion, a diagnosis of severe sepsis and/or septic shock will be adjudicated on the medical file and 30-day follow-up by an expert panel blind for the biomarkers studied. ICu admission and death will be recorded by the medical file and 30-day phone interview.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sepsis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma and sera
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients attending the ED and suspected to have sepsis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient attending the ED and suspected to have sepsis by the emergency physician
             after clinical exam

        Exclusion Criteria:

          -  patient minor under 18-year

          -  pregnancy

          -  anticipated no follow-up possible (homeless...)

          -  Refusal to participate

          -  patient under curators, prisoner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pierre Hausfater, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARCEAR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>pierre hausfater, MD PhD</last_name>
    <phone>(33)142177240</phone>
    <email>pierre.hausfater@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>laetitia velly</last_name>
    <email>vellylaetitia@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>pierre hausfater, PhD</last_name>
      <phone>(33)142177240</phone>
      <email>pierre.hausfater@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>laetitia velly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aiham ghazali</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>yonathan freund</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean-marc cavaillon, PhD</last_name>
      <email>jean-marc.cavaillon@pasteur.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 24, 2016</lastchanged_date>
  <firstreceived_date>February 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital de la Salpétrière</investigator_affiliation>
    <investigator_full_name>Hausfater Pierre</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>biomarker</keyword>
  <keyword>prognostic</keyword>
  <keyword>emergency department</keyword>
  <keyword>diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
